Investigating the effects of Qingre Lifei decoction combined with terbutaline in treating male patients with acute exacerbation of chronic obstructive pulmonary disease

This study aimed to evaluate the therapeutic efficacy of Qingre Lifei decoction combined with terbutaline in men suffering from acute exacerbation of chronic obstructive pulmonary disease (COPD). 100 male patients with COPD acute exacerbation admitted to our hospital between May 2020 and May 2023, were enrolled and randomly assigned to an experimental group and a control group (n = 50 each) based on a computer-generated randomization table. As a control treatment, a terbutaline nebulizer solution was inhaled alongside with conventional Western medicine. The experimental group additionally received Qingre Lifei Decoction. A comparison was made between the therapeutic effects of the two treatment methods. The experimental group exhibited a significantly higher overall effective rate than the control group (p < 0.05). One month after treatment, the experimental group showed significantly higher forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and FEV1/FVC ratios than the control group (p < 0.05). C-reactive protein (CRP), white blood cells (WBC), and neutrophils (N) in the experimental group were significantly lower than the control group one month after treatment (p < 0.05). Compared to controls, the arterial oxygen partial pressure (PaO2) and oxygen saturation (SaO2) levels in the experimental group were significantly higher, and the carbon dioxide partial pressure (PaCO2) levels were significantly lower (p < 0.05). Adverse drug reactions incidence did not differ between both groups (p > 0.05). In men with acute exacerbations of COPD, Qingre Lifei decoction combined with terbutaline nebulization can be effective in improving breathing symptoms and functional ventilation. It is safe and worthy of wider clinical promotion.

Qingre Lifei decoction; Chronic obstructive pulmonary disease; Terbutaline nebulization

[1] Yan L, Chen M, Wei H, Ma H. Construction and validation of nomogram prediction model for risk of acute heart failure in patients with acute exacerbation of chronic obstructive pulmonary disease. Medicine. 2024; 103: e36840.

[2] Tian H, Chao YC, Hu J, Song YL. Immunotherapy advances for lung cancer combined with chronic obstructive pulmonary disease. Chinese Journal of Tuberculosis and Respiratory Diseases. 2024; 47: 70–74. (In Chinese)

[3] Morimoto C, Matsumoto H, Nomura N, Sunadome H, Nagasaki T, Sato S, et al. Sputum microbiota and inflammatory subtypes in asthma, COPD, and its overlap. Journal of Allergy and Clinical Immunology: Global. 2023; 3: 100194.

[4] Priego-Jiménez S, Cavero-Redondo I, Pascual-Morena C, Martínez-García I, Martínez-Vizcaíno V, Álvarez-Bueno C. Effect of different exercise programs on lung function in people with chronic obstructive pulmonary disease: a network meta-analysis of RCTs. Annals of Physical and Rehabilitation Medicine. 2024; 67: 101792.

[5] Zhu X, Meng X, Lei N, Shen Z, Li X, Song H, et al. Chinese herbal injections plus Western Medicine on inflammatory factors for patients with acute exacerbation of chronic obstructive pulmonary disease: a systematic review and network meta-analysis. Journal of Thoracic Disease. 2023; 15: 1901–1918.

[6] Wen G, Xuanlin LI, Hulei Z, Siyuan L, Yang X, Jiansheng LI. Effectiveness of Chinese herbal medicine combined with conventional medicine on acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Journal of Traditional Chinese Medicine. 2023; 43: 212–220.

[7] Wang X, Gao Y, Zhu J, Zhang X, Wu F, Yang Q, et al. Bioinformatics analysis of the molecular mechanism of Qibaipingfei Capsule in the regulation of chronic obstructive pulmonary disease related immune cells. Chinese Journal of Cellular and Molecular Immunology. 2022; 38: 961–966. (In Chinese)

[8] Kham-Ai P, Heaton K, Xiao C, Wheeler P. Systematic review and meta-analysis of psychological distress and acute exacerbation of chronic obstructive pulmonary disease and consequences. Nursing Research. 2024; 73: 62–71.

[9] Lee JE, Nguyen HQ, Fan VS. Inflammatory markers and fatigue in individuals with moderate to severe chronic obstructive pulmonary disease. Nursing Research. 2024; 73: 54–61.

[10] Phuthornchai K, Banharak S, Panpanit L, Chanaboon S. Effects of symptom management program on selected health outcomes among older people with chronic obstructive pulmonary disease: a quasi-experimental study. Scientific Reports. 2023; 13: 22265.

[11] Xu X, Huang M, Duan X, Liu H, Zhang W, Li D. Compound glycyrrhiza oral solution alleviates oxidative stress and inflammation by regulating SRC/MAPK pathway in chronic obstructive pulmonary disease. Immunopharmacology and Immunotoxicology. 2022; 44: 1032–1043.

[12] Jia Y, He T, Wu D, Tong J, Zhu J, Li Z, et al. The treatment of Qibai Pingfei capsule on chronic obstructive pulmonary disease may be mediated by Th17/Treg balance and gut-lung axis microbiota. Journal of Translational Medicine. 2022; 20: 281.

[13] Luo Q, Peng X, Zhang H. Effect of terbutaline plus doxofylline on chronic obstructive pulmonary disease. American Journal of Translational Research. 2021; 13: 6959–6965.

[14] Li Y, Xu Z, Qing C, Zhang H, Wu X, Yang J. Clinical efficacy of glucocorticoid and terbutaline in the treatment of acute exacerbation of chronic obstructive pulmonary disease. American Journal of Translational Research. 2021; 13: 7029–7034.

[15] Sun Z, Zhao W, Yang K, Li X, Yu P. Efficacy and safety of traditional Chinese medicine injections in the treatment of chronic obstructive pulmonary disease: a protocol for systematic review and network meta-analysis. Medicine. 2021; 100: e27324.

[16] Pradhan S, Rituparna S, Dehury H, Dhall M, Singh YD. Nutritional profile and pharmacological aspect of Houttuynia cordata Thunb. and their therapeutic applications. Pharmacological Research—Modern Chinese Medicine. 2023; 9: 100311.

[17] Gul H, Hussain A, Javaid F, Khan KU, Basit A, Arafat M, et al. Novel insights into the anti-asthmatic effect of Raphanus sativus L. (Raphani Semen): targeting immune cells, inflammatory pathways and oxidative stress markers. Journal of Ethnopharmacology. 2024; 325: 117851.

[18] Zhang HJ, Chen RC, Sun GB, Yang LP, Zhu YD, Xu XD, et al. Corrigendum to “Protective effects of total flavonoids from Clinopodium chinense (Benth.) O. Ktze on myocardial injury in vivo and in vitro via regulation of Akt/Nrf2/HO-1 pathway” [Phytomedicine 40 (2018) 88–97]. Phytomedicine. 2024; 155514.

[19] Luan F, Zou J, Zhang X, Zeng J, Peng X, Li R, et al. An update review of extraction, purification, structural features, bioactivities, and applications of Schisandra chinensis polysaccharides. International Journal of Biological Macromolecules. 2024; 262: 130030.

[20] Li T, Yu F, Zhang T, Wang X, Sun Y, Shuai G, et al. Modulatory effects of fermented Polygonatum cyrtonema Hua on immune homeostasis and gut integrity in a dextran-sulfate-sodium-induced colitis model. Food & Function. 2024; 15: 3158–3173.

[21] Huang P, Lin X, Liu Y, Hou Z. The efficacy and safety of combined traditional Chinese and western medicine in the treatment of chronic obstructive pulmonary disease complicated with respiratory failure: a systematic review and meta-analysis study. Annals of Palliative Medicine. 2022; 11: 1102–1111.

[22] Li L, Li CL, Sun HZ, Yan Y, Shi Q, Si DX, et al. Analysis of animal models of stable chronic obstructive pulmonary disease based on clinical features of traditional Chinese medicine and western medicine. China Journal of Chinese Materia Medica. 2021; 46: 4575–4580. (In Chinese)

[23] Qiu X, Zhang Y, Luo Y, Zhang Y. SmCYP71D373 of Salvia miltiorrhiza catalyzes the methyl oxidation reaction of tanshinone IIA-19 position. Industrial Crops and Products. 2024; 212: 118323.

[24] Li J, Liu X, Dong H, Zheng W, Feng S, Tian Y, et al. Effective-constituent compatibility-based analysis of Bufei Yishen formula, a traditional herbal compound as an effective treatment for chronic obstructive pulmonary disease. Journal of Integrative Medicine. 2020; 18: 351–362.